Priming the pancreatic cancer tumor microenvironment for checkpoint-inhibitor immunotherapy.
Single agent immunotherapy is effective against several cancers, but has failed against poorly immunogenic cancers, including pancreatic cancer. Evaluation of pancreatic tumors following treatment with an experimental vaccine (Lutz et al. Cancer Immunology Research 2014) suggests that vaccination primes the tumor microenvironment (TME) for checkpoint-inhibitor immunotherapy, and supports a new platform for evaluating checkpoint-inhibitors in poorly immunogenic cancers.
Department of Oncology; Johns Hopkins University School of Medicine ; Baltimore, MD USA ; The Sidney Kimmel Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA.
Eric R
ER
Lutz
Department of Oncology; Johns Hopkins University School of Medicine ; Baltimore, MD USA ; The Sidney Kimmel Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care; Johns Hopkins University School of Medicine , Baltimore, MD USA ; Graduate Program of Cellular and Molecular Medicine; Johns Hopkins University School of Medicine , Baltimore, MD USA.
Heather
H
Kinkead
Department of Oncology; Johns Hopkins University School of Medicine ; Baltimore, MD USA ; The Sidney Kimmel Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; Department of Pathology.
Elizabeth M
EM
Jaffee
Department of Oncology; Johns Hopkins University School of Medicine ; Baltimore, MD USA ; The Sidney Kimmel Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Skip Viragh Center for Pancreatic Cancer Research and Clinical Care; Johns Hopkins University School of Medicine , Baltimore, MD USA ; The Sol Goldman Pancreatic Cancer Center; Johns Hopkins University School of Medicine , Baltimore, MD USA ; Department of Surgery; Johns Hopkins University School of Medicine , Baltimore, MD USA.
Lei
L
Zheng
pancreatic cancer; tumor immunotherapy; tumor vaccines